MCL-1 and BCL-xL-dependent resistance to the BCL-2 inhibitor ABT-199 can be overcome by preventing PI3K/AKT/mTOR activation in lymphoid malignancies

Supporters

Support the authors with ResearchCoin

Tip RSC

Journal

Cell Death and Disease

Topics

Biology

Biochemistry

Chemistry

Medicine

Immunology

Show all topics

DOI

10.1038/cddis.2014.525

License

CC-BY

Other Formats

PDF